Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors [clinicaltrials:NCT00301756]

Bio2RDF identifier

NCT00301756

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00301756

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00301756

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

65

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00301756 arm group e9160e94a4a6d1bbe5ca9f711f7366a2 [clinicaltrials_resource:NCT00301756/arm-group/e9160e94a4a6d1bbe5ca9f711f7366a2]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This phase II trial is ...... zymes needed for cell growth.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Belinostat in Treating Patient ...... Low Malignant Potential Tumors

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:4fcb4ecd30ef1226ac79f8d813e151ba]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:0c93effdc5efefa1166df7a80b369d6e]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:189d3209a33f8ddbf91f884ee8d63018]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:2e26ab1bf28184ed72bc8b3f897bce3c]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:4866409c275e6815c15992e0d80ae022]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:5358896e6166374d2d36eff7ba8ac5fd]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:837e07d575b92eaa2f321a7a26a20f39]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:97262337528a58fc5e45d3092239b23c]

Efficacy of belinostat in terms of complete or partial response; disappearance of all target lesions or at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Up to 5 years [clinicaltrials_resource:b9d1a31569769b1a7141c782b61d8c44]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... riodically for up to 5 years.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00301756 [clinicaltrials_resource:5be956883f0e12d02fa5f13b3bd89e15]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

belinostat [clinicaltrials_resource:b8beff2a998139efd449c4e90a9965f0]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Belinostat [clinicaltrials_resource:2ad87339ac06154385bb0758365e90f3]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2013-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Cancer Institute (NCI) [clinicaltrials_resource:a5725923b7e37779ae6f8b04acb7f59c]

location [clinicaltrials_vocabulary:location]

Juravinski Cancer Centre at Hamilton Health Sciences [clinicaltrials_resource:22944e966cf6907809be1614f0c1b15a]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00301756

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase 2 Study of PXD101 in P ...... orderline (LMP) Ovarian Tumors

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

NCI-2009-00144

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Amit Oza [clinicaltrials_resource:1342643e30b73628f661539324325dfb]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

PHL-041

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

National Cancer Institute (NCI) [clinicaltrials_resource:a5725923b7e37779ae6f8b04acb7f59c]

start date [clinicaltrials_vocabulary:start-date]

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00301756 study design [clinicaltrials_resource:1f4e822e5161708b1715902c7f7c9ac8]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00301756

verification date [clinicaltrials_vocabulary:verification-date]

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00301756

http://www.w3.org/2001/XMLSchema#string

title

Belinostat in Treating Patient ...... Low Malignant Potential Tumors

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Belinostat in Treating Patient ...... s [clinicaltrials:NCT00301756]

@en